List of Luzu drug patents

Luzu is owned by Bausch.

Luzu contains Luliconazole.

Luzu has a total of 4 drug patents out of which 0 drug patents have expired.

Luzu was authorised for market use on 14 November, 2013.

Luzu is available in cream;topical dosage forms.

Luzu can be used as treatment of fungal infections.

The generics of Luzu are possible to be released after 28 April, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9199977 BAUSCH Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
Sep, 2033

(10 years from now)

US9012484 BAUSCH Crystal and pharmaceutical preparation containing the same crystal
Sep, 2033

(10 years from now)

US9453006 BAUSCH Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931 BAUSCH Method of evaluating pharmaceutical preparation containing luliconazole and index substance
Apr, 2034

(11 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Market Authorisation Date: 14 November, 2013

Treatment: Treatment of fungal infections


More Information on Dosage

LUZU family patents




United States




European Union






Korea, Republic of

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in